Clinical Trial Update: Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL [Phase 1]

View source ↗

Summary

Phase 1 safety study of blinatumomab (MT103), a bispecific T-cell engager, in patients with relapsed non-Hodgkin's lymphoma; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Blinatumomab (MT103) (Blinatumomab)

Snippet

Sponsor: Amgen Research (Munich) GmbH | Conditions: Non-Hodgkin's Lymphoma, Relapsed | Phase 1 | Status: COMPLETED | Results posted: 2015-01-16